This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Sep;15(10):1044-5.

doi: 10.1016/S1470-2045(14)70403-6. Epub 2014 Aug 19.

Cilengitide in glioblastoma: when did it fail?

Olivier L Chinot¹

Affiliations

PMID: 25163907
DOI: 10.1016/S1470-2045(14)70403-6

Comment

Cilengitide in glioblastoma: when did it fail?

Olivier L Chinot. Lancet Oncol. 2014 Sep.

. 2014 Sep;15(10):1044-5.

doi: 10.1016/S1470-2045(14)70403-6. Epub 2014 Aug 19.

Author

Olivier L Chinot¹

Affiliation

¹ Aix-Marseille University, AP-HM, Department of Neuro-Oncology, CHU Timone, 13005 Marseille, France. Electronic address: olivier.chinot@ap-hm.fr.

PMID: 25163907
DOI: 10.1016/S1470-2045(14)70403-6

No abstract available

PubMed Disclaimer

Comment on

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Stupp R, et al. Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19. Lancet Oncol. 2014. PMID: 25163906 Clinical Trial.

Similar articles

Does cilengitide deserve another chance?
Tucci M, Stucci S, Silvestris F. Tucci M, et al. Lancet Oncol. 2014 Dec;15(13):e584-e585. doi: 10.1016/S1470-2045(14)70462-0. Epub 2014 Nov 24. Lancet Oncol. 2014. PMID: 25456376 No abstract available.
Does cilengitide deserve another chance?-Authors' reply.
Stupp R, Picard M, Weller M. Stupp R, et al. Lancet Oncol. 2014 Dec;15(13):e585-e586. doi: 10.1016/S1470-2045(14)71121-0. Epub 2014 Nov 24. Lancet Oncol. 2014. PMID: 25456377 No abstract available.
End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.
Mason WP. Mason WP. Neuro Oncol. 2015 May;17(5):634-5. doi: 10.1093/neuonc/nov018. Epub 2015 Feb 13. Neuro Oncol. 2015. PMID: 25681307 Free PMC article. No abstract available.
Glioblastoma in the elderly.
Chamberlain MC. Chamberlain MC. Cancer Treat Res. 2015;163:159-70. doi: 10.1007/978-3-319-12048-5_10. Cancer Treat Res. 2015. PMID: 25468231 Review.
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G. Weller M, et al. Future Oncol. 2010 Sep;6(9):1407-14. doi: 10.2217/fon.10.113. Future Oncol. 2010. PMID: 20919826 Review.

See all similar articles

Cited by

Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.
Ayo A, Laakkonen P. Ayo A, et al. Pharmaceutics. 2021 Apr 2;13(4):481. doi: 10.3390/pharmaceutics13040481. Pharmaceutics. 2021. PMID: 33918106 Free PMC article. Review.
The Effects of αvβ3 Integrin Blockage in Breast Tumor and Endothelial Cells under Hypoxia In Vitro.
Casali BC, Gozzer LT, Baptista MP, Altei WF, Selistre-de-Araújo HS. Casali BC, et al. Int J Mol Sci. 2022 Feb 3;23(3):1745. doi: 10.3390/ijms23031745. Int J Mol Sci. 2022. PMID: 35163668 Free PMC article.
Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
Alday-Parejo B, Stupp R, Rüegg C. Alday-Parejo B, et al. Cancers (Basel). 2019 Jul 12;11(7):978. doi: 10.3390/cancers11070978. Cancers (Basel). 2019. PMID: 31336983 Free PMC article. Review.
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Echavidre W, Picco V, Faraggi M, Montemagno C. Echavidre W, et al. Pharmaceutics. 2022 May 13;14(5):1053. doi: 10.3390/pharmaceutics14051053. Pharmaceutics. 2022. PMID: 35631639 Free PMC article. Review.
Integrin-based therapeutics: biological basis, clinical use and new drugs.
Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. Ley K, et al. Nat Rev Drug Discov. 2016 Mar;15(3):173-83. doi: 10.1038/nrd.2015.10. Epub 2016 Jan 29. Nat Rev Drug Discov. 2016. PMID: 26822833 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program